Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00336323 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

A Phase 2 study of Diabetic Retinopathy, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target
20
Study locations

NCT00336323 is a Phase 2 study of Diabetic Retinopathy that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 121 participants, below the 1,674-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00336323, a Phase 2 study of Diabetic Retinopathy, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target
20
Study locations

Study Summary

This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning a phase 3 trial. In addition, this study will provide preliminary data on the safety of intravitreally administered Avastin in subjects with DME.

Conditions Studied

Diabetic Retinopathy

Interventions

  • DRUG Bevacizumab
  • PROCEDURE Laser Photocoagulation

Study Locations (20)

California

  • Loma Linda University Health Care, Dept. of Ophthalmology - Loma Linda
  • Southern California Desert Retina Consultants, MC - Palm Springs
  • California Retina Consultants - Santa Barbara
  • Bay Area Retina Associates - Walnut Creek

Florida

  • Retina Vitreous Consultants - Fort Lauderdale
  • Central Florida Retina Institute - Lakeland

Indiana

  • Raj K. Maturi, M.D., P.C. - Indianapolis
  • American Eye Institute - New Albany

Kentucky

  • Retina and Vitreous Associates of Kentucky - Lexington
  • Paducah Retinal Center - Paducah

Maryland

  • Elman Retina Group, P.A. - Baltimore
  • Retina Consultants of Delmarva, P.A. - Salisbury

Massachusetts

  • Ophthalmic Consultants of Boston - Boston
  • Joslin Diabetes Center - Boston

North Carolina

  • Charlotte Eye, Ear, Nose and Throat Assoc., PA - Charlotte
  • Wake Forest University Eye Center - Winston-Salem

Georgia

  • Southeast Retina Center, P.C. - Augusta

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2006-06
Est. Completion 2008-02
Phase Phase 2

Sponsor

Jaeb Center for Health Research

119 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00336323

The ClinicalTrials.gov registry entry for NCT00336323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,674-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (93% lower). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT00336323 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT00336323 about?

NCT00336323 is a clinical study titled "A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)". This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning a phase 3 trial. In addition, this study will provide preliminary dat...

What is the current status of trial NCT00336323?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2006-06. Estimated completion is 2008-02.

What conditions does trial NCT00336323 study?

This clinical trial studies the following conditions: Diabetic Retinopathy.

What interventions are being tested in trial NCT00336323?

The interventions under investigation include: Bevacizumab (DRUG), Laser Photocoagulation (PROCEDURE).

Who is sponsoring clinical trial NCT00336323?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00336323 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Retinopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Retinopathy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.